+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID06796907

Evaluating Safety and Effects of Mocertatug Rezetecan Combined with Anti-Cancer Agents in Adults with Advanced Solid Tumors

Led by GlaxoSmithKline · Updated on 2026-11-02

305

Participants Needed

83

Research Sites

68 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying treatments for advanced solid tumors, which are cancers that have spread and often become resistant to existing therapies. This trial evaluates the safety, tolerability, how the body processes Mocertatug Rezetecan Mo-Rez, and its effectiveness when combined with other cancer medicines. Participants include adults with advanced solid tumors who have not responded to standard treatments, cannot tolerate them, or lack effective options. Participants will receive Mo-Rez intravenously, combined either with Dostarlimab for endometrial cancer or with Bevacizumab for ovarian cancer. The study is randomized, with multiple treatment groups, and includes two parts Part A focusing on dose-limiting toxicities and safety over about 7 to 22 months, and Part B assessing confirmed tumor response and survival outcomes up to approximately 37 months. During the trial, participants undergo regular evaluations including tumor assessments by RECIST criteria, biomarker analyses from tumor tissue samples, vital sign monitoring, lab tests, and ECGs. Researchers track adverse events, immune responses, drug concentrations, and quality of life measures. The study lasts up to nearly three years with ongoing safety and efficacy monitoring throughout.

CONDITIONS

Brief Title

A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)

Research Team

U

US GSK Clinical Trials Call Center

E

EU GSK Clinical Trials Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here